Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12991073 | 1.00 | OPRL1 (0.46) | OPRL1KDM4EKMT2APKMMEN1 | |
| SCHEMBL12991116 | 0.88 | KDM4E (0.50) | OPRL1KDM4EKMT2APKMMEN1 | |
| SCHEMBL3536719 | 0.88 | KDM4E (0.50) | OPRL1KDM4EKMT2APKMMEN1 | |
| SCHEMBL12991383 | 0.88 | KDM4E (0.43) | OPRL1KDM4EKMT2APKMMEN1 | |
| SCHEMBL12991280 | 0.86 | OPRL1 (0.40) | OPRL1KDM4EKMT2APKMMEN1 | |
| SCHEMBL3540520 | 0.86 | OPRL1 (0.40) | OPRL1KDM4EKMT2APKMMEN1 | |
| SCHEMBL14318676 | 0.83 | KDM4E (0.34) | OPRL1KDM4EALDH1A1HTTHPGD | |
| SCHEMBL14274099 | 0.83 | KDM4E (0.34) | OPRL1KDM4EALDH1A1HTTHPGD | |
| SCHEMBL12991315 | 0.82 | OPRL1 (0.36) | OPRL1KDM4EKMT2APKMMEN1 | |
| SCHEMBL12991349 | 0.82 | KDM4E (0.38) | OPRL1KDM4EKMT2APKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858790-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858790-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858790-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2040706-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmceuticals Incorporated (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080033002-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-07 | — | — | US | disclosed |
| US-20080033002-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-07 | — | — | US | disclosed |
| US-20080033002-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-07 | — | — | US | disclosed |
| WO-2008005295-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008005295-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033002-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | OPRL1 69/4885KDM4E 3396/4885KMT2A 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.